AstraZeneca divests Atacand commercial rights to Cheplapharm
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to…
AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus in over 70 countries to…